Amgen's SWOT analysis: stock poised for growth amid challenges in obesity market

Amgen Inc. reported robust Q1 2025 results, surpassing revenue and EPS estimates, and issued optimistic 2025 guidance, underpinned by strong profitability and a 14-year dividend growth record. The company's growth trajectory is largely tied to its advanced pipeline, notably the ultra-long-acting obesity treatment MariTide, now in Phase 3 after positive Phase 2 data, and its expanding biosimilar segment. Despite these prospects, Amgen navigates intense competition in the obesity market from oral GLP-1 agonists and potential pressures on mature products, making MariTide's successful differentiation critical for sustained market leadership.

Analysis

Amgen demonstrated strong financial health in its Q1 2025 results, with revenue of $9.09 billion and EPS of $5.31 surpassing consensus estimates. The company's full-year 2025 guidance projects continued growth, forecasting revenues between $34.3 billion and $35.7 billion. This performance is supported by a robust 69% gross profit margin, a 14-year history of consecutive dividend growth, and a P/E ratio of 25.2, which is presented as favorable against near-term growth. The investment thesis hinges on two primary drivers: the high-potential obesity treatment, MariTide, and a burgeoning biosimilars portfolio. MariTide, an ultra-long-acting injectable, has shown significant weight loss in Phase 2 trials and is now in a pivotal Phase 3 program. However, its market potential is challenged by intense competition, particularly from convenient oral GLP-1 agonists like Eli Lilly's orforglipron. Concurrently, Amgen's biosimilar segment is proving to be a significant growth engine, with the Eylea biosimilar Pavblu generating $99 million in its first quarter, indicating a strong capability to capture market share and diversify revenue streams away from mature products like Repatha, which itself saw 41% volume growth but faces long-term pressures.

Key Decisions for Investors

• Investors should closely monitor upcoming 2025 catalysts, particularly Phase 3 data for the obesity drug MariTide, as its clinical profile and market positioning against oral competitors will be critical in determining Amgen's long-term growth trajectory.
• Evaluate the expanding biosimilar portfolio, evidenced by Pavblu's strong launch, as a key source of durable revenue that can provide a partial hedge against the high-risk, high-reward nature of the MariTide pipeline.
• Consider the stock's defensive financial characteristics, including its consistent 14-year dividend growth and strong free cash flow yield, which offer a degree of stability and shareholder return amidst the competitive uncertainties in the biopharmaceutical landscape.